AstraZeneca, Ionis stocks tumble after heart drug fails key trial

AstraZeneca and Ionis Pharmaceuticals shares fell sharply on Thursday after the companies said Wainua failed to meet its main goal in a late-stage trial in transthyretin amyloid cardiomyopathy, or ATTR-CM.

The result weakens the case for expanding Wainua beyond its current approval for hereditary transthyretin amyloidosis with polyneuropathy, a different condition. It also dents AstraZeneca's cardiovascular pipeline narrative and narrows the longer-term commercial upside for Ionis.

Trial setback

The companies said the Phase 3 CARDIO-TTRansform study did not show a statistically significant benefit on the composite outcome of cardiovascular mortality and recurrent cardiovascular events. They said Wainua was generally well tolerated, but the top-line result did not support the cardiomyopathy indication.

AstraZeneca said the readout was disappointing, while also arguing that the data may still add to scientific understanding of treatment approaches for ATTR-CM. The company did not announce a new regulatory path for the drug.

ATTR-CM is a rare and often fatal heart condition caused by misfolded transthyretin proteins that can accumulate in the heart. A successful trial would have opened a larger market for Wainua in a disease area that already attracts strong commercial interest.

Market reaction

The stock move was immediate. Coverage from later in the day said both AstraZeneca and Ionis fell sharply after the announcement, with some analysts characterizing the selloff as larger than the clinical miss alone might justify.

Barron's reported that investors were still digesting the implications of the failure, while the Wall Street Journal, the Financial Times and other outlets noted that the companies said the trial did not meet its primary objective. The repeated same-day reporting reinforced the core message: the readout was a clear setback for both companies.

Ionis does not sell Wainua alone. The drug was developed with AstraZeneca, and the cardiomyopathy miss therefore affects both companies' strategic and financial outlooks.

For AstraZeneca, the disappointment lands in a closely watched cardiovascular area where the company has been trying to broaden its pipeline. For Ionis, it removes a possible expansion route for a product already on the market in a different indication.

What comes next

The companies said they will continue analyzing the full data set. They also said they plan to share results with the scientific community at the European Society of Cardiology Congress in August.

That means investors and clinicians will still be waiting for fuller context, including whether any subgroup signal emerges and whether the dataset changes the interpretation of the miss. No new filing plan has been disclosed.

The broader ATTR-CM market remains competitive, with approved treatments already available from rivals including Alnylam, Pfizer and BridgeBio. Wainua's failure to strengthen its case in the disease makes the expansion race harder for AstraZeneca and Ionis.

For now, the immediate story is straightforward: a late-stage miss in a closely watched heart-disease trial knocked down both stocks and reduced the odds that Wainua becomes a major cardiomyopathy franchise.